Ixazomib ( DrugBank: Ixazomib )

4 diseases
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎1
16クロウ・深瀬症候群1
28全身性アミロイドーシス4
51全身性強皮症1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03783416
(ClinicalTrials.gov)		June 1, 201910/12/2018SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple SclerosisSafety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple SclerosisDrug: Ixazomib (NINLARO®) capsules / Matching placebo capsulesQueen Mary University of LondonTakeda Pharmaceuticals International, Inc.Not yet recruiting18 Years65 YearsAll72Phase 1United Kingdom

16. クロウ・深瀬症候群

臨床試験数 : 13 /  薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 75
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02921893
(ClinicalTrials.gov)		October 31, 201626/9/2016Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeIxazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromePlasmacytoma;POEMS SyndromeDrug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire AdministrationMayo ClinicNational Cancer Institute (NCI)Active, not recruiting18 YearsN/AAll21Early Phase 1United States

28. 全身性アミロイドーシス

臨床試験数 : 267 /  薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05451771
(ClinicalTrials.gov)		October 26, 20226/7/2022Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisAn Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain AmyloidosisAL AmyloidosisDrug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: Dexamethasone Oral, 10 mg;Drug: Dexamethasone Oral, 20 mg;Drug: Daratumumab Injection;Drug: Bendamustine;Drug: Pomalidomide;Drug: Ixazomib;Drug: Venetoclax MTD with DexamethasoneRajshekhar Chakraborty, MDGenentech, Inc.Recruiting18 YearsN/AAll53Phase 1/Phase 2United States
2NCT03618537
(ClinicalTrials.gov)		August 2, 20182/8/2018Ixazomib Maintenance Study in Patients With AL AmyloidosisIxazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) AmyloidosisAL AmyloidosisDrug: Ixazomib;Drug: DexamethasoneMemorial Sloan Kettering Cancer CenterTufts Medical Center;Vanderbilt University Medical CenterRecruiting18 YearsN/AAll47Phase 2United States
3NCT03283917
(ClinicalTrials.gov)		February 7, 201813/9/2017Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisA Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisNewly Diagnosed Primary Amyloidosis;Recurrent Primary Amyloidosis;Refractory Primary AmyloidosisBiological: Daratumumab;Drug: Dexamethasone;Drug: IxazomibM.D. Anderson Cancer CenterJanssen Pharmaceuticals;TakedaRecruiting18 YearsN/AAll20Phase 1United States
4NCT03236792
(ClinicalTrials.gov)		June 12, 201720/7/2017Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL AmyloidosisPhase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL AmyloidosisAL AmyloidosisDrug: Ixazomib;Drug: Cyclophosphamide;Drug: DexamethasoneIcahn School of Medicine at Mount SinaiMillennium Pharmaceuticals, Inc.Completed18 YearsN/AAll28Phase 1/Phase 2United States

51. 全身性強皮症

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04837131
(ClinicalTrials.gov)		April 28, 20215/4/2021A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease PatientsA Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung DiseaseSystemic Sclerosis;Scleroderma;Diffuse Systemic Sclerosis;Diffuse Scleroderma;Diffuse Cutaneous Systemic Sclerosis;Diffuse Cutaneous Scleroderma;Progressive Systemic Sclerosis;Progressive Scleroderma;Scleroderma, Systemic;Scleroderma, Diffuse;Progressive;Systemic Sclerosis, Diffuse;Systemic; Sclerosis, Progressive;Scleroderma of Lung;Scleroderma With Pulmonary Involvement;Systemic Sclerosis Pulmonary;Systemic Sclerosis With Lung Involvement;Interstitial Lung Disease;Pulmonary Fibrosis InterstitialDrug: IxazomibW. Leroy GriffingNULLRecruiting18 YearsN/AAll12Phase 2United States

先頭へ